In this study, fatty acid binding protein was used to protect an ischemic heart from reperfusion injury. Isolated rat heart was preperfused in the presence of 1.4 ,uM liposome-bound (Circulation Research 1990;66:1535-1543 
T he precise biochemical mechanisms for membrane injury during myocardial ischemia and reperfusion remain obscure despite many investigations. However, a growing body of evidence shows that among many factors, accumulation of membrane-derived fatty acids and their esters may play a significant role in the pathogenesis of ischemic and reperfusion injury.1-3 Several factors may be responsible for the accumulation of fatty acids and their esters during ischemia. First, /3-oxidation of fatty acids is significantly inhibited during ischemia, which leads to the accumulation of free fatty acids (FFAs), fatty acyl coenzyme A (CoA) esters, and long-chain fatty acyl carnitines.45 Another possibility is the breakdown of membrane phospholipids during ischemia and reperfusion, resulting in accumulation of nonesterified fatty acids and lysophospholipids. [6] [7] [8] These accumulated lipids can cause severe membrane injury and may represent one of the causes for ischemic and reperfusion injury.
Recent studies indicate the presence of an intracellular fatty acid binding protein (FABP) in the heart that can bind to FFAs and their thioesters with high affinity.9-1" These FABPs, which represent about 4% of the soluble protein in the heart,12 were found to be lost during ischemia and reperfusion. 13 Therefore, we hypothesized that if additional FABPs could be added to the heart, they might provide adequate protection to the ischemic and reperfused heart.
In this study, we perfused isolated rat heart with highly purified FABP before the ischemic insult. Reperfusion of heart treated with FABP demonstrated significant improvement in preserving highenergy phosphate compounds and maintaining coronary flow, and showed less tissue injury compared with control hearts.
Materials and Methods

Isolation and Purification of Fatty Acid Binding Protein
Rat heart cytosolic FABP was prepared according to the procedure described by Ockner et al14 with slight modification. In brief, the cytosol (100,OOOg supernatant containing 5 mg protein/ml) was dialyzed against 10 mM Tris HCl (pH 7.5) (buffer A), and the dialyzate was loaded onto a Sephadex G-75 (100xl cm) column (Pharmacia, Piscataway, New Jersey) previously equilibrated with buffer A. The second peak eluting in the low molecular weight region (25-10 kDa) was loaded onto a diethylaminoethanol (DEAE)-cellulose (10x2 cm) column (Whatman Lab Sales Inc., Hillsboro, Oregon) previously equilibrated with buffer A. After absorption, the column was washed with five bed volumes of buffer A, then a linear gradient of 0-0.4 M KCl (five bed volumes) in buffer A was applied. The fractions eluting in 0.1 M KCl concentration were pooled and assayed for FABP activity. The DEAE-cellulose fractions containing FABP activity were dialyzed and the pH adjusted to 5.0, and then they were applied onto a carboxymethylcellulose (10x 1 cm) column (Whatman) previously equilibrated with 10 mM sodium acetate (pH 5.0) (buffer B). After The extracted fatty acids were methylated and separated by gas chromatography (Hewlett-Packard, Palo Alto, California).20 Quantification of acyl groups was done by comparing the areas with the heptadecanoyl methyl ester areas. Long-chain acyl CoAs and long-chain acyl carnitines were estimated as the differences of the fatty acid levels in the hydrolyzed sample (total cytosolic lipids) and the fatty acid levels of the nonhydrolyzed sample.
Long-chain acyl CoA, long-chain acyl carnitine, and FFA were also measured in the whole heart using our previously described methods. Both treated and untreated groups showed a decrease in coronary flow during the first 15 minutes of perfusion after mounting the heart in the Langendorff apparatus; however, these changes were not statistically significant. These coronary flows stabilized from an average of 12-14 ml/min/g heart weight to about 10 ml/min/g heart weight within 15 minutes, and remained unchanged even after 30 minutes of perfusion (data not shown). These changes were consistently reflected in each rat and may be attributed to the stabilization process. If FABP was added after this stabilization, no further drop of coronary flow was noticed. The flow remained unchanged in control heart not subjected to ischemia and reperfusion for up to 30 minutes after the addition of FABP (10.5±1.2 ml/min/g), suggesting that FABP did not cause any inotropic effect.
In the present study, FABP-treated heart showed significant improvement in coronary flow compared Global ischemia was then induced by terminating coronary flow, followed by 30 minutes reperfiusion.
Coronary flow was measured at indicated time intervals as described in "Materials and Methods." 30' with the untreated group. For example, the coronary flow after 5 minutes of reperfusion was only 10.5 ml/min/g in control heart, compared with 11.7 ml/min/g in the experimental group (Figure 3) . After 30 minutes of reperfusion, the coronary flow in the FABP-treated heart was 14 ml/min/g, which was significantly higher compared with the corresponding control group (8.5 ml/min/g). This indicated better myocardial performance for the FABP-treated hearts.
Effects of Fatty Acid Binding Protein on the Release of Creatine Kinase and Lactic Acid Dehydrogenase
The release of CK and LDH is considered to be a reliable indicator for cellular injury and tissue necrosis. Release of CK ( Figure 4 ) and LDH ( Figure 5 ) from the heart followed a similar pattern and increased progressively during the entire period of reperfusion. However, increases in CK and LDH release during reperfusion were less in the FABP group compared with the nontreated group. At the end of 30 minutes of reperfusion, release of CK and LDH was significantly less (p<0.05) in heart of the FABP group compared with corresponding controls. Because FABP is known to bind FFAs and their esters, we separated the FABP-bound fatty acids and their esters from the FFAs in the cytosolic fraction by Lipidex chromatography. Analysis of the fatty acid profiles of cytosolic protein-bound FFAs revealed that FABP bound all the long-chain fatty acids (Table 4 ). In particular, 18:1, 18:2, 20:4, and total FFAs showed significantly higher binding with FABP compared with the control group. In addition, FABP also bound with long-chain fatty acyl CoAs and long-chain fatty acyl carnitines ( Table 5 ). The fatty acid profiles of those long-chain fatty acyl esters demonstrated that FABP significantly enhanced binding in the 18:1, 18:2, and total FFAs compared with corresponding controls. Discussion Among the many factors responsible for myocardial cellular injury during ischemia and reperfusion, FIGURE 7 . Effect of fatty acid binding protein (FABP) on content of lipid peroxidation in heart as a function of ischemia and reperfusion. Isolated rat heart was perfused 15 minutes in the presence or absence of FABP (1.4 ,uM) . Global ischemia was then induced by termninating coronary flow, followed by 30 minutes of reperfusion. Perfusate was withdrawn at indicated time intervals. Malondialdehyde, a presumptive marker for lipid peroxidation, was assayed in the perfusate as described in "Materials and Methods." during ischemia and reperfusion.
accumulation of nonesterified fatty acids (including arachidonic acid and lysophospholipids) represents a major concern.1-7 Accumulation of arachidonic acid has also been observed after a relatively brief period of ischemia followed by reperfusion.6,21 It is generally believed that arachidonic acid and lysophospholipids are derived from the breakdown of membrane phospholipids primarily because of the activation of the deacylation pathway and a defective reacylation system.67 Recent studies from our laboratory have also indicated that these lipids may be derived from other metabolic pathways, including the signal transducing systems.17 In addition, inhibition of f3-oxidation during ischemic insult also results in accumulation of long-chain fatty acids and their acyl CoA thioesters.4,5
The detrimental effects of these membranederived lipids in the pathogenesis of ischemic and reperfusion injury have been reviewed.1,2 FFAs and lysophospholipids can cause myocardial arrhythmias by their detergentlike action.12 They can also inhibit a number of key enzymes, including Na+,Ca+-ATPase22 and adenosine nucleotide translocase.23 Accumulation of nonesterified fatty acids in concert with loss of membrane phospholipids can also alter the fluidity of the membrane lipid bilayer.24 Prolonged ischemia can ultimately lead to physical disruption of the myocardial membrane and loss of its ability to function as a protective barrier, resulting in Once the accumulation of lipids occurs, mammalian heart becomes defenseless. Unless outside interventions are immediately administered, the lipids may cause serious myocardial injury. Until recently, it was generally believed that there had been no naturally occurring myocardial defense system against lipid abnormality. Recent studies, however, recognize that such a system may exist in the heart. These are nonenzyme proteins (referred to as FABP), which exist in appreciable quantities in mammalian hearts (4-8% of soluble proteins). A very limited number of studies have been performed on myocardial FABP, and its precise nature and physiological functions within the cell remain largely speculative. It has been suggested that FABP may temporarily store or sequestrate FFAs and fatty acyl CoA esters, thereby modulating or buffering their detrimental effects.9-'6 In addition, FABP may help to shuttle the poorly soluble long-chain fatty acids and fatty acyl CoAs from the site of entry or synthesis to the site of esterification or oxidation, thus behaving as an intracellular counterpart of serum albumin.25 Either of these properties of FABPs makes them ideal protective agents during myocardial ischemia. Recent studies demonstrate a significant loss of FABP from heart during ischemia and reperfusion.13 Therefore, we hypothesized that if additional FABP can be supplied to the heart, it might provide adequate protection to ischemic and reperfused myocardium. FABP isolated and prepared from rat heart was found to be of high purity by SDS-PAGE. Purified FABP was found to bind 2 nmol fatty acid/nmol protein. Even though FABP used in this study was of relatively low molecular weight (14 kDa), we still used liposome-bound FABP in our study to ascertain the entrance of FABP inside the cell. FABP was found to provide adequate protection to the ischemic reperfused heart as judged by the preservation of high-energy phosphate compounds, increased coronary flow, and reduced release of CK and LDH, presumptive markers for cellular injury. However, most of the beneficial effects were found after 30 minutes of reperfusion, so we performed some additional experiments to examine whether these beneficial effects persisted beyond 30 minutes of reperfusion. Our results indicated higher coronary flow and lower LDH, and CK release by FABP persisted even after 60 minutes of reperfusion (results not shown).
In this study, we used FABP before the ischemic insult. Our attempt to use FABP at the onset of reperfusion was not successful owing to its failure to provide any myocardial protection.
FABP by itself did not appear to have any effect on the heart. When an isolated heart was perfused for up to 30 minutes in the presence of FABP without any intervention, no apparent changes in coronary flow and myocardial contractility were observed. In each experiment, however, a drop in coronary flow was observed after mounting the heart in the perfusion apparatus, irrespective of FABP treatment. This drop in coronary flow was consistent for each experiment during its first 15 minutes, which might be attributed to stabilization.
Our results clearly demonstrated that the internally added FABP entered the cell and bound with FFAs and their esters. Because the majority of FABP is located in the cytosolic compartment, we isolated the FABP-bound FFAs and their esters in the heart cytosol to study the binding of FABP. In addition, FABP reduced arachidonic acid incorporation in the FFA pool, with corresponding increases in incorporation into the membrane phospholipids. This suggests that turnover of arachidonic acid and its reacylation into phospholipids were enhanced by FABP. 1) preserving membrane phospholipids and enhancing arachidonic acid uptake by the heart by stimulating the reacylation step and 2) binding with FFAs and their esters, which may be produced during ischemic insult. The protection of ischemic heart by FABP may be considered to be an interesting facet of the pathobiology of ischemic and reperfusion injury. Accumulation of FFAs and their long-chain esters and lysophospholipids in concert with loss of FABP during ischemia strongly suggests a role of FABP in myocardial ischemic and reperfusion injury. Our results support this hypothesis and clearly demonstrate a protective role of FABP in ischemic heart.
